Omkar Pharmachem Stock Price Today (NSE: 532167)

Omkar Pharmachem

27.00+0.00 (+0.00%)
Market Closed

Fundamental Score

...

Omkar Pharmachem Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Omkar Pharmachem share price today is 27.00, up +0.00% on NSE/BSE as of 19 June 2026. Omkar Pharmachem (532167) is a Small-cap company in the Chemicals & Petrochemicals sector with a market capitalisation of 27.06 (Cr). The 52-week high for 532167 share price is 29.74 and the 52-week low is 25.50. At a P/E ratio of 150.33x, 532167 is currently trading above its industry average P/E of 22.17x. The company has a Return on Equity (ROE) of 2.14% and a debt-to-equity ratio of 0.01.

Omkar Pharmachem Share Price Chart — NSE/BSE Historical Performance

No data
High
28.31
Low
27.00
Volume
0.18181818181818182
Change
-3.67%

Omkar Pharmachem share price chart: -3.67% return over the past month. 52-week high ₹29.74, 52-week low ₹25.50.

Omkar Pharmachem — Last 10 Trading Days

DateOpenHighLowCloseVolume
27.0027.0027.0027.000.00 (Cr)
27.0027.0027.0027.000.00 (Cr)
27.0027.0027.0027.000.00 (Cr)
27.0027.0027.0027.000.00 (Cr)
27.0027.0027.0027.000.00 (Cr)
27.0027.0027.0027.000.00 (Cr)
27.0027.0027.0027.000.00 (Cr)
27.0027.0027.0027.000.00 (Cr)
27.0027.0027.0027.000.00 (Cr)
27.0027.0027.0027.000.00 (Cr)

Omkar Pharmachem — Last 12 Months Price History

MonthOpenHighLowCloseChange
27.0027.0027.0027.00+0.00%
28.0328.3127.0027.00-3.67%
29.5029.5028.0328.03-4.98%
29.5029.5029.5029.50+0.00%
29.7429.7429.5029.50-0.81%
29.7429.7429.7429.74+0.00%
28.3329.7428.3329.74+4.98%
28.3328.3328.3328.33+0.00%
25.5028.3325.5028.33+11.10%
25.5626.8325.5025.50-0.23%
25.6825.6825.6825.68+0.00%
25.6825.6825.6825.68+0.00%

Returns & Performance

Poor

Return on Equity (ROE)

2.14%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

3.04%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

49.79%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Omkar Pharmachem Valuation Check

Poor

Price to Earnings (P/E)

150.33x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

22.17x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Poor

Promoter Holding

0.03%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-40.00%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

0.00%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

60.95%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

22.59%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

22.59%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.01x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

14.50x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

1.02 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Omkar Pharmachem Fundamental Analysis & Valuation Benchmarking

Educational evaluation of 532167 across key market metrics for learning purposes.

Positive Indicators

7 factors identified

Strong Operating Margins (49.79%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Consistent Growth Track Record (60.95% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Excellent EPS Growth (22.59% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (22.59% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.01)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (14.50x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

6 factors identified

Below-Average Return on Equity (2.14%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (3.04%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Premium Valuation Risk (P/E: 150.33x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Profit Decline Concern (-40.00%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Low Promoter Commitment (0.03%)

Observation: Reduced promoter stake may indicate limited confidence.

Analysis: Low promoter holding may raise questions about management commitment.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Omkar Pharmachem vs Commodity Chemicals Peers

Peer Comparison - Commodity Chemicals

Compare Omkar Pharmachem with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
29/100
27
₹27.06
150.3
Average
2.14%
Poor
3.04%
Poor
0.0
Excellent
22.59%
Excellent
60.95%
Excellent
0.00%
SRF Ltd...
SRF503806
49.8/100
2737
₹86606.52
53.5
Average
10.37%
Average
12.27%
Average
0.3
Excellent
4.40%
Average
15.30%
Excellent
0.25%
14.9/100
775
₹20261.08
62.2
Average
1.20%
Poor
3.96%
Poor
0.3
Excellent
-47.92%
Poor
7.53%
Good
1.38%
57/100
1448
₹17120.52
17.4
Average
15.56%
Good
15.67%
Good
0.7
Good
94.55%
Excellent
17.00%
Excellent
0.74%
52.8/100
516
₹7381.56
11.6
Average
7.08%
Poor
9.57%
Poor
0.0
Excellent
3.30%
Average
8.86%
Good
3.58%
Ghcl Ltd...
GHCL500171
40.4/100
463
₹5520.31
9.7
Average
18.57%
Good
24.19%
Excellent
0.0
Excellent
8.63%
Good
-0.75%
Poor
2.09%
19.7/100
18
₹5397.73
9306.4
Average
2.12%
Poor
2.57%
Poor
0.0
Excellent
173.71%
Excellent
0.00%
24.4/100
222
₹4503.74
-5.93%
Poor
1.83%
Poor
1.0
Good
28.15%
Excellent
0.00%
68.7/100
1972
₹4106.65
43.7
Average
32.05%
Excellent
41.76%
Excellent
0.1
Excellent
38.64%
Excellent
27.58%
Excellent
0.22%
28/100
687
₹3866.17
25774.5
Average
-1.13%
Poor
-0.34%
Poor
0.1
Excellent
8.37%
Good
3.01%
59.7/100
72
₹3614.14
23.9
Average
17.58%
Good
23.34%
Excellent
0.0
Excellent
17.17%
Excellent
12.90%
Good
0.63%

Omkar Pharmachem Quarterly Performance

Latest quarterly metrics for 532167 — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

0.00%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-40.00%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

60.95%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

22.59%

Compounded annual net profit growth over 5 years

Omkar Pharmachem Technical Indicators

SMA 50, SMA 200, RSI and volume signals for 532167 — calculated from daily price history

0RSI 14
Oversold — RSI 0

Selling pressure is heavy — potential reversal zone.

SMA 50
29
▼ Price below SMA 50 — Short-term bearish
SMA 200
28
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
0K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Omkar Pharmachem Financial Statements

Annual income statement, balance sheet and cash flow for Omkar Pharmachem (532167) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Omkar Pharmachem

About 532167 (Omkar Pharmachem)

Omkar Pharmachem (532167) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Chemicals & Petrochemicals sector wit...h a current market capitalisation of ₹27.06 (Cr). Omkar Pharmachem has delivered a Return on Equity (ROE) of 2.14% and a ROCE of 3.04%. The debt-to-equity ratio stands at 0.01, reflecting the company's capital structure. Investors tracking 532167 share price can monitor key metrics including P/E ratio, promoter holding of 0.03%, and quarterly earnings growth.

Company Details

Symbol:532167
Industry:Chemicals & Petrochemicals
Sector:Commodity Chemicals
Website:N/A

532167 Share Price: Frequently Asked Questions

What is the current share price of Omkar Pharmachem?

Omkar Pharmachem (532167) trades at ₹27.00 on BSE. Market cap ₹27.06 (Cr). Educational data only.

What is the P/E ratio of Omkar Pharmachem?

Omkar Pharmachem has a P/E of 150.33x vs industry average 22.17x.

What is the Bull Run score for Omkar Pharmachem?

Omkar Pharmachem has a Bull Run score of 29/100 based on 25+ financial parameters.

Does Omkar Pharmachem pay dividends?

Omkar Pharmachem has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Omkar Pharmachem?

Omkar Pharmachem has ROE of 2.14%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Omkar Pharmachem?

Omkar Pharmachem has debt-to-equity of 0.01.

Is Omkar Pharmachem a good investment?

Bull Run gives Omkar Pharmachem a score of 29/100. This is not investment advice — consult a SEBI-registered advisor.